A Self‐Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple‐Negative Breast Cancer
Small · 2025
DOI: 10.1002/smll.202410214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Xianquan Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Transplant Biology, Laboratory of Basic Medicine, Fuzong Clinical College of Fujian Medical University (900th Hos…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Photochemotherapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, Scientific Startup Foundation of Fujian Medical University.
Abstract (Originalsprache)
The efficacy of immunotherapy in triple‐negative breast cancer (TNBC) is significantly hindered by its low immunogenicity and immunosuppressive tumor microenvironment. Non‐invasive photodynamic therapy (PDT) is increasingly recognized as a potential immunotherapeutic stimulant in the treatment of TNBC. However, photodynamic immunotherapy is constrained by tumor hypoxia and excessive inflammation suppression during the course of treatment. Herein, a simple and efficacious biomedicine is formulated to overcome adverse influences by amplifying photodynamic immunotherapy, thereby stimulating the systemic immune response. Specifically, the approach targeted tumor delivery by employing specific agents such as the photosensitizer (verteporfin), the hypoxic ameliorator (atovaquone), and the cyclooxygenase‐2/prostaglandin E2 (COX‐2/PGE2) signaling blocker (celecoxib). More importantly, the biomedicine effectively ameliorated hypoxia and inhibited COX‐2/PGE2 signaling, thereby amplifying PDT‐induced immunogenic cell death. This, in turn, enhanced the efficacy of photodynamic immunotherapy and triggered a robust immune response cascade. Notably, the self‐amplifying photodynamic biomedicine significantly inhibited primary tumors, distal tumors, lung metastases, and post‐operative recurrence while maintaining high biocompatibility. To sum up, the work provides a viable cascade stimulation approach and an efficient biomedical nanoplatform, offering a novel strategy for photodynamic immunotherapy of TNBC in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Provincial Key Laboratory of Transplant Biology, Laboratory of Basic Medicine, Fuzong Clinical College of Fujian Medical University (900th Hospital of the Joint Logistics Support Force), Fuzhou, 350025, China.
- Department of Oncology, Fuzong Clinical College of Fujian Medical University (900th Hospital of the Joint Logistics Support Force), Fuzhou, 350025, China.
- Department of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of the Joint Logistics Support Force), Fuzhou, 350025, China.
ORCID-Profile: Xianquan Feng
Förderung
- Natural Science Foundation of Fujian Province
- Scientific Startup Foundation of Fujian Medical University
Zitieren
APA
Feng, X., Zhang, Y., Lin, W., Li, J., Wu, F., Lu, Q., Song, H., Zhang, H., Lan, F., & Lu, J. (2025). A Self‐Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple‐Negative Breast Cancer. Small. https://doi.org/10.1002/smll.202410214
Vancouver
Feng X, Zhang Y, Lin W, Li J, Wu F, Lu Q, et al. A Self‐Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple‐Negative Breast Cancer. Small. 2025. doi:10.1002/smll.202410214
BibTeX
@article{Feng2025,
author = {Feng, Xianquan and Zhang, Yan and Lin, Wanjing and Li, Jing and Wu, Fei and Lu, Qingyu and Song, Hongtao and Zhang, Hao and Lan, Fenghua and Lu, Jun},
title = {A Self‐Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple‐Negative Breast Cancer},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202410214}
}
EUVIMED